These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 28376088)
41. CXCL2-mediated ATR/CHK1 signaling pathway and platinum resistance in epithelial ovarian cancer. Nie S; Wan Y; Wang H; Liu J; Yang J; Sun R; Meng H; Ma X; Jiang Y; Cheng W J Ovarian Res; 2021 Sep; 14(1):115. PubMed ID: 34474677 [TBL] [Abstract][Full Text] [Related]
42. miR-874-3p mitigates cisplatin resistance through modulating NF-κB/inhibitor of apoptosis protein signaling pathway in epithelial ovarian cancer cells. Wang Y; Yan C; Qi J; Liu C; Yu J; Wang H Mol Cell Biochem; 2022 Jan; 477(1):307-317. PubMed ID: 34716858 [TBL] [Abstract][Full Text] [Related]
43. Elevated β-catenin activity contributes to carboplatin resistance in A2780cp ovarian cancer cells. Barghout SH; Zepeda N; Xu Z; Steed H; Lee CH; Fu Y Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):173-8. PubMed ID: 26522223 [TBL] [Abstract][Full Text] [Related]
44. Galectin-1 overexpression promotes progression and chemoresistance to cisplatin in epithelial ovarian cancer. Zhang P; Zhang P; Shi B; Zhou M; Jiang H; Zhang H; Pan X; Gao H; Sun H; Li Z Cell Death Dis; 2014 Jan; 5(1):e991. PubMed ID: 24407244 [TBL] [Abstract][Full Text] [Related]
45. Novel glycolipid agents for killing cisplatin-resistant human epithelial ovarian cancer cells. Moraya AI; Ali JL; Samadder P; Liang L; Morrison LC; Werbowetski-Ogilvie TE; Ogunsina M; Schweizer F; Arthur G; Nachtigal MW J Exp Clin Cancer Res; 2017 May; 36(1):67. PubMed ID: 28499442 [TBL] [Abstract][Full Text] [Related]
46. Genetic and epigenetic heterogeneity of epithelial ovarian cancer and the clinical implications for molecular targeted therapy. Bai H; Cao D; Yang J; Li M; Zhang Z; Shen K J Cell Mol Med; 2016 Apr; 20(4):581-93. PubMed ID: 26800494 [TBL] [Abstract][Full Text] [Related]
47. Potential of platinum-resensitization by Wnt signaling modulators as treatment approach for epithelial ovarian cancer. Kaltofen T; Preinfalk V; Schwertler S; Fraungruber P; Heidegger H; Vilsmaier T; Vattai A; Czogalla B; Mayr D; Mahner S; Jeschke U; Trillsch F J Cancer Res Clin Oncol; 2020 Oct; 146(10):2559-2574. PubMed ID: 32681294 [TBL] [Abstract][Full Text] [Related]
48. Targeting chromosomal instability and tumour heterogeneity in HER2-positive breast cancer. Burrell RA; Juul N; Johnston SR; Reis-Filho JS; Szallasi Z; Swanton C J Cell Biochem; 2010 Nov; 111(4):782-90. PubMed ID: 20665662 [TBL] [Abstract][Full Text] [Related]
49. [Polymorphisms of ERCC1 gene and outcomes in epithelial ovarian cancer patients with platinum-based chemotherapy]. Qi BL; Li Y; Wang N; Zhou RM; Hu P; Kang S Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):847-52. PubMed ID: 24444563 [TBL] [Abstract][Full Text] [Related]
50. Overexpression of JARID1B is associated with poor prognosis and chemotherapy resistance in epithelial ovarian cancer. Wang L; Mao Y; Du G; He C; Han S Tumour Biol; 2015 Apr; 36(4):2465-72. PubMed ID: 25663457 [TBL] [Abstract][Full Text] [Related]
51. Upregulation of lncRNA AB073614 functions as a predictor of epithelial ovarian cancer prognosis and promotes tumor growth in vitro and in vivo. Zeng S; Liu S; Feng J; Gao J; Xue F Cancer Biomark; 2019; 24(4):421-428. PubMed ID: 30909184 [TBL] [Abstract][Full Text] [Related]
52. NSAID-activated gene 1 mediates pro-inflammatory signaling activation and paclitaxel chemoresistance in type I human epithelial ovarian cancer stem-like cells. Kim KH; Park SH; Do KH; Kim J; Choi KU; Moon Y Oncotarget; 2016 Nov; 7(44):72148-72166. PubMed ID: 27708225 [TBL] [Abstract][Full Text] [Related]
53. Misaligned Chromosomes are a Major Source of Chromosomal Instability in Breast Cancer. Tucker JB; Bonema SC; García-Varela R; Denu RA; Hu Y; McGregor SM; Burkard ME; Weaver BA Cancer Res Commun; 2023 Jan; 3(1):54-65. PubMed ID: 36968230 [TBL] [Abstract][Full Text] [Related]
54. The Lipidomic Analyses in Low and Highly Aggressive Ovarian Cancer Cell Lines. Zhao Z; Cai Q; Xu Y Lipids; 2016 Feb; 51(2):179-87. PubMed ID: 26661829 [TBL] [Abstract][Full Text] [Related]
55. High ATP6V1B1 expression is associated with poor prognosis and platinum‑based chemotherapy resistance in epithelial ovarian cancer. Han GH; Yun H; Chung JY; Kim JH; Cho H Oncol Rep; 2023 May; 49(5):. PubMed ID: 36999629 [TBL] [Abstract][Full Text] [Related]
56. MK-2206 sensitizes BRCA-deficient epithelial ovarian adenocarcinoma to cisplatin and olaparib. Whicker ME; Lin ZP; Hanna R; Sartorelli AC; Ratner ES BMC Cancer; 2016 Jul; 16():550. PubMed ID: 27465688 [TBL] [Abstract][Full Text] [Related]
57. MicroRNA let-7g acts as tumor suppressor and predictive biomarker for chemoresistance in human epithelial ovarian cancer. Biamonte F; Santamaria G; Sacco A; Perrone FM; Di Cello A; Battaglia AM; Salatino A; Di Vito A; Aversa I; Venturella R; Zullo F; Costanzo F Sci Rep; 2019 Apr; 9(1):5668. PubMed ID: 30952937 [TBL] [Abstract][Full Text] [Related]
58. High frequency of putative ovarian cancer stem cells with CD44/CK19 coexpression is associated with decreased progression-free intervals in patients with recurrent epithelial ovarian cancer. Liu M; Mor G; Cheng H; Xiang X; Hui P; Rutherford T; Yin G; Rimm DL; Holmberg J; Alvero A; Silasi DA Reprod Sci; 2013 May; 20(5):605-15. PubMed ID: 23171677 [TBL] [Abstract][Full Text] [Related]
60. Chromosomal instability in untreated primary prostate cancer as an indicator of metastatic potential. Miller ET; You S; Cadaneanu RM; Kim M; Yoon J; Liu ST; Li X; Kwan L; Hodge J; Quist MJ; Grasso CS; Lewis MS; Knudsen BS; Freeman MR; Garraway IP BMC Cancer; 2020 May; 20(1):398. PubMed ID: 32380981 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]